ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO138

Arterial Stiffness and Immunosuppressive Regimen in Renal Transplants Recipients

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Heleniak, Zbigniew, Medical University of Gdansk, Gdansk, Poland
  • Ruszkowski, Jakub, Medical University of Gdansk, Gdansk, Poland
  • Halleck, Fabian, Charité Universitätsmedizin Berlin, Berlin, Germany
  • Illersperger, Sarah M., Charité Universitätsmedizin Berlin, Berlin, Germany
  • Brakemeier, Susanne, Charité Universitätsmedizin Berlin, Berlin, Germany
  • Debska-Slizien, Alicja, Medical University of Gdansk, Gdansk, Poland
  • Budde, Klemens, Charite Universitatsmedizin Berlin, Berlin, Germany

Reduction of cardiovascular influences on the long-term survival rates of renal transplant recipients (RTRs) The aim of the study was to assess the relation between immunosuppression and pulse wave velocity in RTRs.


103 RTRs, who were visiting outpatient clinic in February 2018 were enrolled into the study. eGFR was calculated with the CKD-EPI formula. Arterial stiffness was assessed by means of brachial-ankle and carotid-femoral pulse wave velocity (baPWV, cfPWV) measured by ABI-system 100. Patient characteristics and results were described by median and interquartile range (IQR) for continuous variables and by frequencies for categorical variables.


Median age of 103 studied RTRs was 53 (37-61) years, 64 (62.1%) patients were male. Details are presented in figure 1.
The immunosuppressive regimen was as follow: calcineurin inhibitors (CNI) (68.9/17.5% on TAC/CsA, respectively), antiproliferative agents (48.5/47.6% on MPS/MMF, respectively), steroids (39.8/7.8/3.9% on methylprednisolone/prednisolone/prednisone, respectively), belatacept (6.8%). There was linear correlation between CsA level and cfPWV (p <0,05). CsA concentration/dose (C/D) ratio correlated with baPWV (p<0,05). Neither tacrolimus daily dose nor concentration correlated with baPWV and cfPWV, respectively. C/D ratio of TAC correlated with cfPWV p<0,05).
There were observed linear correlations between age of the patients, duration of renal replacement therapy and baPWV, cfPWV (p<0,05). eGFR correlated negatively with cfPWV (p<0,05)


CsA and TAC were administered in the majority of the study population.
CNI increased the arterial stiffness.
Both CsA and TAC C/D ratio had the influence on PWV.
Age, RRT duration time and eGFR correlated with arterial stiffness markers